Kelie Reece

Medicine · Health Sciences

11h-index648citations38works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hormonal and reproductive studies(13), Cancer, Hypoxia, and Metabolism(9), Prostate Cancer Treatment and Research(7), Cancer, Lipids, and Metabolism(5), Blood groups and transfusion(4)

Publications38 total

Figure S2 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Figure S3 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Table S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Data from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Figure S4 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Figure S3 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Figure S2 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Supplemental Figure Legends from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Figure S4 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Figure S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Supplemental Figure Legends from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Data from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Figure S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
Table S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
2023Open Access
FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations
Clinical Cancer Research·2022· 36 citedOpen Access
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Clinical Cancer Research·2021· 160 citedOpen Access
FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
The Oncologist·2020· 82 citedOpen Access
Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx
Molecular Cancer Research·2017· 18 citedOpen Access
Dual Targeting of the Androgen Receptor and Hypoxia-Inducible Factor 1α Pathways Synergistically Inhibits Castration-Resistant Prostate Cancer Cells
Molecular Pharmacology·2015· 58 citedOpen Access
Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer.
Journal of Clinical Oncology·2015
page 1 of 2Next →

Frequent Co-authors

Douglas K. Price(23), William D. Figg(23), Tristan M. Sissung(22), Sarah Troutman(19), Cindy H. Chau(18), David Venzon(17), Ariel M. Ley(17), Jonathan D. Strope(15), Edel M. McCrea(15), Shaunna Beedie(15), Cody J. Peer(15), Suneet Shukla(15), Jennifer C. van Velkinburgh(15), Phoebe Huang(15), Nilay Thakkar(15), Stefan Brenner(15), Wooin Lee(15), Maria J. Merino(15), Walter Jäger(15), Tessa Campbell(14)